FDA delays Capricor's deramiocel PDUFA date to review new data

FDA DecisionderamiocelNegative

AI Analysis

Summary

The FDA has extended its PDUFA decision date for Capricor Therapeutics' deramiocel, a Duchenne muscular dystrophy therapy, to review additional data for a more niche indication. The delay indicates the agency requires further information before making a regulatory decision.

Outcome Details

FDA extended PDUFA date to review additional data for niche indication

Importance:7/10

Sentiment:

-0.60

FDAPDUFA delayDuchenne muscular dystrophyregulatory setback

Related Companies

$CAPR

Read the original article

Published by Endpoints News on August 24, 2026 3:10 PM

Read Original